Latest Breaking News On - Vp international markets at medison - Page 1 : comparemela.com

KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval in the United States and the European Union PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ Today, Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, is pleased to announce the approval of KIMMTRAK(tebentafusp) by Health Canada and Therapeutics Goods Administration (TGA) for the treatment of unresectable or metastatic uveal melanoma (mUM), a rare and aggressive form of melanoma that affects the eye. KIMMTRAK was developed by Immunocore Holdings plc ("Immunocore"), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. The approval will enable Medison to commercia

United statesNew zealandUnited kingdomImmunocore immMarcus butlerDara willisMark moyerVictor papamoniodisMedison pharmaMeir jakobsohnTherapeutics goods administrationTumor immunotherapy programGage communicationsVp international markets at medisonEuropean unionCorporate communications